ClinicaliQ Trial Snapshot
- Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study — Recruiting • Phase IV • NCT05935358.
- Recombinant factor VIII safely prevents bleeding during surgery in haemophilia A patients already on emicizumab prophylaxis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis Conditions: Severe Hemophilia A Interventions: Nuwiq Lead Sponsor: Octapharma Planned Enrollment: 28 participants